464 related articles for article (PubMed ID: 29109299)
1. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK
Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299
[TBL] [Abstract][Full Text] [Related]
2. Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study.
Koye DN; Montvida O; Paul SK
Drugs; 2020 Apr; 80(5):477-487. PubMed ID: 32141024
[TBL] [Abstract][Full Text] [Related]
3. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
4. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
5. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
6. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
Fu AZ; Sheehan JJ
Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
[TBL] [Abstract][Full Text] [Related]
7. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
8. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
9. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
10. Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.
Heintjes EM; Overbeek JA; Hall GC; Prieto-Alhambra D; Lapi F; Hammar N; Bezemer ID
Clin Ther; 2017 Nov; 39(11):2296-2310.e14. PubMed ID: 29108837
[TBL] [Abstract][Full Text] [Related]
11. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
Rathmann W; Bongaerts B; Kostev K
Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
[TBL] [Abstract][Full Text] [Related]
12. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.
Vashisht R; Jung K; Schuler A; Banda JM; Park RW; Jin S; Li L; Dudley JT; Johnson KW; Shervey MM; Xu H; Wu Y; Natrajan K; Hripcsak G; Jin P; Van Zandt M; Reckard A; Reich CG; Weaver J; Schuemie MJ; Ryan PB; Callahan A; Shah NH
JAMA Netw Open; 2018 Aug; 1(4):e181755. PubMed ID: 30646124
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
14. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
Seino Y; Kuwata H; Yabe D
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):102-9. PubMed ID: 27186364
[TBL] [Abstract][Full Text] [Related]
16. Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
Montvida O; Green JB; Atherton J; Paul SK
Diabet Med; 2019 Apr; 36(4):491-498. PubMed ID: 30306620
[TBL] [Abstract][Full Text] [Related]
17. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
[TBL] [Abstract][Full Text] [Related]
18. Dispensation Patterns of Glucose-Lowering Drugs in Newly Diagnosed Type 2 Diabetes: Routine Data Analysis of Insurance Claims in Germany.
Bongaerts B; Kollhorst B; Kuss O; Pigeot I; Rathmann W
Exp Clin Endocrinol Diabetes; 2022 Sep; 130(9):587-595. PubMed ID: 34942670
[TBL] [Abstract][Full Text] [Related]
19. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
